secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001104659-25-101410
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics updates on GX-03 phase 2 eczema trial: 25% enrolled, topline 2026; $85M GEM facility
--------------------------------------------------------------------------------

- Phase 2 trial of GX-03 (topical IL-36/IL-31 inhibitor) for moderate-severe eczema: ~25% of targeted sample completed, no safety concerns; topline results expected in 2026.
- Company completed dilution-sparing direct listing with $85M GEM Global Yield on-demand financing vehicle to reduce reliance on future equity offerings.
- Intranasal vaccine initiative advancing; in-vivo studies scheduled to commence in Q4 2025.
- Shareholder webinar held today, October 22, 2025 at 2:00 PM ET to review milestones and capital strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000110465925101410/0001104659-25-101410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000110465925101410/tm2529242d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-101410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer